| Code | 9379B | ||||||||||
| MA number | 44/0266/16-S | ||||||||||
| Product Form: | imp sip 1x10,8 mg (aplik.inj.ihl.+implantát) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Zentiva k.s., Czechia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 48 | ||||||||||
| Container: | needle applicator | ||||||||||
| Route of admin.: | Subcutaneous use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(3) hybrid application |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Reseligo 10,8 mg_01/2021.doc
|
| PIL: |
PIL_Reseligo 10,8 mg_01/2021.doc
|
| Dokument: |
DHPC_Reseligo_04.07.2025.pdf
|
| Safety feature | Yes |
| Data update: | 26.04.2023 |
